|1.||Protonotariou, Efthimia: 1 article (01/2007)|
|2.||Rizos, Demetrios: 1 article (01/2007)|
|3.||Sarandakou, Angeliki: 1 article (01/2007)|
|4.||Rio, M-C: 1 article (07/2006)|
|5.||Mathelin, C: 1 article (07/2006)|
|6.||Koehl, C: 1 article (07/2006)|
|7.||Quaranta, M: 1 article (04/2004)|
|8.||Coviello, M: 1 article (04/2004)|
|9.||Abbate, I: 1 article (04/2004)|
|10.||Daniele, A: 1 article (04/2004)|
|1.||Breast Neoplasms (Breast Cancer)
05/01/2001 - "To assess the usefulness of Mucin-like carcinoma-associated antigen (MCA) in monitoring pregnant patients with breast cancer. "
10/01/1997 - "The usefulness of serum measurements of mucin-like carcinoma associated antigen (MCA) in 100 women at presentation with breast cancer was evaluated. "
10/01/1997 - "Mucin-like carcinoma associated antigen (MCA) at presentation with breast cancer."
07/01/1997 - "Increased levels of mucin-like carcinoma-associated antigen (MCA) in breast cancer patients with no evidence of disease following the treatment of the primary disease created a dilemma of 'to treat' or 'wait and see'. "
07/01/1997 - "A high value of mucin-like carcinoma associated antigen (MCA), CA-15.3 or H23, in a woman known to have a diagnosis of breast cancer, may reflect presence of disease. "
|2.||Pleural Effusion (Pleural Effusions)
10/01/2000 - "The aim of the present study was to determine the usefulness of simultaneous quantification of carbohydrate antigen 19.9, carbohydrate antigen 125, neuron specific enolase, mucinous-carcinoma-associated antigen, and ferritin in samples of pleural fluids in the malign pleural effusion and its differentiation from benign effusions. "
04/01/1993 - "Mucin-like Carcinoma-associated Antigen (MCA) has been associated with many breast cancers. "
07/01/1988 - "The serum concentration of the new tumor marker MCA (mucinous carcinoma associated antigen) was determined by an enzyme immunoassay kit method, which is based on the use of a monoclonal antibody b12. "
04/01/1997 - "We evaluated the usefulness of the mucin-like carcinoma-associated antigen (MCA) in the fluid of pancreatic cysts for detecting mucinous neoplasms. "
07/01/1990 - "Thus it seems that CA M29 is a promising serum tumor marker in breast cancer."
07/01/1990 - "For comparison, at the cut-off level of 10 kU/1 the CA M29 test was positive in 30/46 (65%) cancer cases, in 16/20 (80%) of cancer patients with nodal involvement, in 9/49 (18%) of the patients with benign breast disease, and in 10/30 (33%) of control subjects. "
10/01/1992 - "[Cytosol concentrations of CAM29 in breast carcinoma. "
10/01/1992 - "MCA (Mucinous Carcinoma-Associated Antigen) levels of 176 breast carcinoma patients were tested postoperatively by serial determination. "
10/01/1992 - "The diagnostic value of mucinous carcinoma-associated antigen (MCA) tests in breast carcinomas."
01/01/1991 - "Clinical value of a mucin-like carcinoma-associated antigen (MCA) in patients with carcinomas of the kidney and the urinary collecting system."
10/01/1990 - "[Determination of MCA, CA 15.3, CA M26, in carcinoma of the breast]."
|5.||Neoplasm Metastasis (Metastasis)
01/01/1991 - "A new tumour marker, mucin-like carcinoma-associated antigen (MCA), was evaluated in 176 breast cancer patients classified either as free of tumour (NED, n = 141) or as having metastases (PD, n = 35). "
07/01/1990 - "When we set the cut-off level at 40 kU/1 for CA M26, 15/46 (33%) of all breast cancer patients, 11/20 (55%) of breast cancer patients with axillary node involvement, 1/1 breast cancer patient with distant metastases, 4/49 (8%) of patients with benign breast disease, and 7/30 (23%) of control subjects were above this cut-off level. "
07/01/1990 - "The determination of mucin like carcinoma associated antigen (MCA) showed a sensitivity of 72% in visceral metastasis of breast cancer, of 25% in metastasis of stomach cancer and of 10.3% in metastasis of colorectal cancer. "
10/01/1996 - "A total of 209 postsurgical breast cancer patients were prospectively monitored with simultaneous serum level estimations of CA 15,3, mucin-like carcinoma-associated antigen (MCA), tumor polypeptide antigen (TPA), and carcinoembryonic antigen (CEA); 141 (67.5%) were free of recurrence and 68 (32.5%) developed metastases during the follow-up. "
|1.||mucinous carcinoma-associated antigen
|4.||Phosphopyruvate Hydratase (Enolase)
|6.||Steroid Receptors (Steroid Receptor)
|9.||Biological Tumor Markers (Tumor Markers)
|10.||Biological Markers (Surrogate Marker)
|1.||Drug Therapy (Chemotherapy)